As employers begin mandating a return to the office, it’s important they consider how remote working has improved the employee experience for workers who are from typically marginalized groups. A 2022 survey of U.S. employees by Future Forum found remote working led to increases in Black knowledge workers’ employee experience scores. Compared to the previous […]
Attention deficit hyperactivity disorder is a neurodevelopmental disorder, affecting up to nine per cent of children and five per cent of adults, said Marie-Hélène Dugal, manager of pharmacy benefit strategy at Medavie Blue Cross, during Benefits Canada’s 2024 Face to Face Drug Plan Management Forum. Diagnosis rates have increased among women and become more common […]
The percentage of claimants filing claims for obesity drugs increased by 43 per cent in 2023, according to a new report by GreenShield. The report, which analyzed the insurer’s 2023 claims data, found diabetes medications saw a 13 per cent increase in cost, accounting for nine per cent of total drug costs in 2023. There […]
Based on multiple studies, it’s estimated that roughly 15 to 20 per cent of the global population is neurodivergent, an umbrella term that includes autism, dyslexia, attention deficit/hyperactivity disorder and Tourette’s syndrome. With a significant portion of employees identifying as neurodiverse, organizations that aren’t tapping into this talent pool could struggle to remain competitive, says […]
In 2023, diabetes medications remained the leading drug category for eligible private insurance claims for the second consecutive year, according to Telus Health’s annual drug trends report. The report, based on claims data from more than 15 million plan members in 2023, found the growing prevalence of diabetes, along with expanded heart failure treatment indications and […]
Canadian employers have taken important steps forward on a range of diversity, equity and inclusion matters. That work continues, particularly in the context of neurodiversity, which applies to an estimated 15 per cent to 20 per cent of the global population. Neurodiversity is a broad category that includes autism, attention-deficit hyperactivity disorder, dyslexia, Tourette’s syndrome, […]
With chronic conditions growing in prevalence among plan members, plan sponsors have their work cut out for them in designing benefits plans that provide adequate health support and employee satisfaction while also being cost effective, said Marie-Hélène Dugal, manager of pharmacy benefit strategy for Medavie Blue Cross, during Benefits Canada’s 2023 Face to Face Drug […]
With hybrid and remote working arrangements becoming increasingly common, employers can take an inclusive approach to help employees with attention deficit hyperactivity disorder feel more engaged and productive, says Dr. Marie-Hélène Geoffroy, a family medicine physician at the Cleveland Clinic Canada. “ADHD needs structure and remote working requires individuals to manage their own schedule and tasks, […]
Three main drug categories — diabetes, asthma and stimulants for attention deficit hyperactivity disorder — accounted for rising drug claims in 2022, according to Lavina Viegas, Telus Health’s director of client account management, speaking during Benefits Canada‘s 2023 Benefits & Pension Summit in June. Referring to Telus Health’s 2023 drug plan trends report, she said […]
Specialty drugs are accounting for a slightly smaller portion of the total eligible amount for all drug claims, declining from 33.6 per cent in 2021 to 33.1 per cent in 2022, according to Telus Health’s annual drug trends report. The report, based on claims data from more than 4.6 million plan members in 2022, found the […]